(FORTUNE Small Business) – Blue-Chip Investors are rallying behind tiny Eximias Pharmaceutical Corp., which has spent four years developing a new chemotherapy drug for liver cancer (see "The Miracle Hunter," in February's FSB). In late March, Eximias, based in Berwyn, Pa., closed a critical $63.5 million private-placement financing deal, among the biggest in biotech this year. The funding allows Eximias to complete clinical testing of the drug, which, with FDA approval, would be the first treatment for inoperable liver cancer. --P.B. GRAY